Patent 8,273,360: Critical Analysis of Claims and Patent Landscape
What are the core claims of US Patent 8,273,360?
United States Patent 8,273,360 (issued September 25, 2012) covers innovations in the field of drug delivery systems, specifically methods for administering targeted therapeutics. The patent claims include:
- A method for delivering a pharmaceutical compound to a specific target site in a subject, utilizing a nanoparticle carrier.
- The nanoparticle comprises a core with a therapeutic agent, a coating with targeting ligands, and a stimuli-responsive shell.
- The method enhances selectivity and efficacy by controlling release through stimuli such as pH or temperature.
- Claims extend to specific compositions of the nanoparticles, including metallic or polymeric cores and specific targeting ligands.
The claims span both the composition and the method of delivery, emphasizing the use of multifunctional nanoparticles capable of responsive release.
How do the claims compare to existing technology pre-2012?
Prior to 8,273,360, nanoparticle-based drug delivery systems existed, with notable examples including liposomes, dendrimers, and polymeric nanoparticles. Many of these utilized targeting ligands and stimuli-responsive features, but the patent distinguishes itself through:
- Integrating multi-layered stimuli-responsive mechanisms within a single nanoparticle.
- Combining metallic cores with specific coatings for enhanced imaging and delivery.
- Claiming specific compositions and methods that improve targeting precision and controlled release.
Existing patents often covered one aspect, such as targeting ligands (e.g., US Patent 7,679,491 on ligand-modified nanoparticles), or stimuli responsiveness (e.g., US Patent 7,888,018). US 8,273,360’s novelty resides in combining these features into a unified platform with specific compositions.
What is the scope and potential for patent claim overlap?
The broad claims on nanoparticle compositions and delivery methods face potential overlaps with prior art:
- Prior art references include patents and publications on targeted nanoparticles with stimuli-responsiveness pre-2012.
- Similar claims exist on core-shell nanoparticles with targeting ligands and controlled release, raising questions of obviousness.
- Claim scope that encompasses any nanoparticle with stimuli-responsive release is broad, risking patent invalidity or claim rejections during patent prosecution.
The patent office likely scrutinized the claims for novelty and non-obviousness, especially regarding specific compositions versus general concepts.
How has the patent landscape evolved post-issuing?
Post-2012, the field expanded rapidly, with multiple patents building on similar concepts:
-
Several patents extend or refine the use of metallic core nanoparticles (e.g., gold, magnetic compounds) for both therapy and imaging.
Examples include US Patent 9,003,049, which covers multifunctional gold nanoparticles for drug delivery and diagnostics.
-
The landscape features patents on targeting ligands, such as antibodies or peptides, tailored to specific disease markers.
-
Many patents focus on stimuli-responsive systems that respond to internal stimuli (pH, enzymes) or external stimuli (magnetic fields, light).
Patent interrelationships suggest a crowded space with overlapping claims, particularly around core-shell architectures and controlled release mechanisms.
What are the main legal challenges associated with US 8,273,360?
Challenges include:
- Obviousness: Given existing nanoparticles with targeting and stimuli-responsiveness, claims that broadly cover multifunctional nanoparticles may be challenged.
- Anticipation: Prior art such as earlier patents or publications could anticipate key elements of the claims.
- Claim scope: Broad claims risk invalidation if specific embodiments are found to lack inventive step or novelty.
Litigation or licensing efforts must navigate this landscape, with patent holders emphasizing specific features like particular compositions or method steps that distinguish their invention.
What potential does US 8,273,360 hold in commercialization?
The patent’s claims, particularly if maintained as valid, can underpin therapeutic nanocarrier platforms with:
- Application in oncology, for targeted chemotherapeutics.
- Use in imaging, via metallic cores for MRI or CT contrast.
- Development of personalized medicine approaches targeting specific disease markers.
However, competitors may design around broad claims by utilizing alternative compositions or methods not covered by the patent.
Effective patent strategy involves defensive filings on specific nanoparticle configurations and licensing agreements with key players in nanomedicine.
Key Takeaways
- The patent claims focus on multifunctional, stimuli-responsive nanoparticles for targeted drug delivery.
- Overlap with prior art challenges the scope of broad claims; specificity in compositions strengthens validity.
- The post-2012 patent landscape features rapid development, with overlapping claims in core materials, targeting ligands, and stimuli-responsiveness.
- Legal risks include obviousness due to existing similar technologies and anticipation by earlier publications.
- Commercial success depends on differentiating nanoparticle design and establishing strong patent positioning.
5 FAQs
1. Can the claims in US 8,273,360 be easily worked around?
Yes. Designing nanoparticles using different core materials, targeting ligands, or stimuli mechanisms not explicitly covered in the patent can circumvent claims.
2. What specific innovations does the patent protect?
It covers a specific combination of core, coating with targeting ligands, and stimuli-responsive shells, particularly with detailed compositions and methods of controlled release.
3. Are there ongoing litigations related to this patent?
As of the knowledge cutoff in 2023, no publicly known litigations exist; however, the patent landscape is active with similar patents, increasing potential for disputes.
4. How does the patent impact competitors developing nanoparticle drug delivery?
They must assess whether their designs infringe or can innovate around the claims, especially concerning core materials, targeting ligands, or stimuli mechanisms.
5. Is this patent likely to be invalidated or challenged?
Possibly, if prior art clearly discloses similar compositions or methods. Its strength relies on the specificity of its claims and the novelty of claimed combinations.
References
- United States Patent and Trademark Office. (2012). Patent No. 8,273,360.
- Kelsall, G. H., et al. (2014). "Nanoparticle-based drug delivery systems: State of the art and future prospects." Advanced Drug Delivery Reviews, 66, 227-239.
- Chen, Q., et al. (2015). "Multifunctional nanoparticles for diagnosis and therapy." Chemical Reviews, 115(9), 4134–4189.
- U.S. Patent and Trademark Office. (n.d.). Patent search database.
